Company|NOUN 29/05/2017_LTP|PERCENT %|NOUN Aurobindo|PROPN Pharma|PROPN 513.70|NUM 638.00_24.2|QUANTITY Cadila_Health|ENT .|PUNCT
456.60_537.20_17.7_Divi|MONEY 's|PART Lab|NOUN .|PUNCT
569.50_661.00|QUANTITY 16.1|NUM Piramal_Enterp|ENT .|PUNCT
2647.05_2998.95|QUANTITY 13.3_Dr|QUANTITY Reddy|PROPN 's|PART Labs|PROPN 2424.85|NUM 2711.95|CARDINAL 11.8_Sun_Pharma|ENT .|PUNCT
Inds|NOUN .|PUNCT
502.85_546.15|QUANTITY 8.6|NUM Cipla_504.15_545.80|QUANTITY 8.3|NUM Lupin_1109.35|QUANTITY 1189.85|NUM 7.3_Glaxosmit_Pharma|ENT 2330.20|NUM 2447.00|NUM 5.0|CARDINAL Glenmark_Pharma|PROPN .|PUNCT
611.40_641.25|QUANTITY 4.9|CARDINAL LTP|NOUN :|PUNCT Last|ADV traded|VERB price|NOUN on|ADP BSE|ENT at|ADP 12:03_p.m__Shares|TIME of|ADP pharmaceutical_companies|NOUN were|VERB back|ADV in|ADP focus|NOUN with|ADP index|NOUN rallying|VERB more_than_10%_from|PERCENT its|ADJ May’s_low|NOUN ,|PUNCT while|ADP Nifty_50|CARDINAL index|NOUN remain|NOUN unchanged|ADJ during|ADP the|DET same_period|NOUN .|PUNCT
In|ADP the_last_three_days|DATE ,|PUNCT Aurobindo_Pharma|ENT ,|PUNCT and|CCONJ Sun_Pharmaceutical_Industries|ENT received|VERB the|DET US_Food_and_Drug_Administration_(USFDA)_approval|NOUN for|ADP their|ADJ respective_drugs|NOUN ,|PUNCT while|ADP Dr_Reddy’s_Laboratories|ENT received|VERB Establishment_Inspection_Report|ENT (|PUNCT EIR|PROPN )|PUNCT from|ADP the|DET US_health_regulator|NOUN for|ADP its|ADJ Miryalaguda_plant|NOUN .|PUNCT
At|ADP 12:05_pm|TIME ;|PUNCT the|DET index|NOUN ,|PUNCT the|DET largest|ADJ gainer|NOUN among|ADP sectoral_indices|NOUN ,|PUNCT was|VERB up|ADV 1.3%_at|PERCENT 9,703|CARDINAL .|PUNCT
The|DET index|NOUN surged|VERB 11%_from|PERCENT its|ADJ recent|ADJ low|NOUN of|ADP 8,758|CARDINAL on|ADP May_29,_2017|DATE and|CCONJ 12.4%_from|PERCENT its|ADJ 52-week|ADJ low_of_8,635_hit|NOUN on|ADP same_day|NOUN in|ADP intra-day_trade|NOUN .|PUNCT
Aurobindo_Pharma|ENT ,|PUNCT and|CCONJ Divi’s_Laboratories|ENT have|VERB rallied|VERB more_than_15%_during|PERCENT the|DET period|NOUN ,|PUNCT while|ADP Dr_Reddy’s_Laboratories|ENT ,|PUNCT Sun_Pharmaceutical_Industries|ENT ,|PUNCT Cipla|ENT and|CCONJ Lupin|ENT were|VERB gained|VERB in|ADP the|DET range|NOUN of|ADP 7%_to|PERCENT 12%.Between_May_15_and_May_29|DATE ,|PUNCT the|DET index|NOUN had|VERB tanked|VERB 14.6%_after|PERCENT most|ADJ the|DET pharma_companies|NOUN reported|VERB disappointing_set|NOUN of|ADP March_quarter_results|NOUN due|ADJ to|ADP continuing|VERB increased_competition|NOUN and|CCONJ the|DET challenging_pricing_environment|NOUN in|ADP US|ENT ,|PUNCT the|DET biggest|ADJ market|NOUN .|PUNCT
On|ADP comparison|NOUN ,|PUNCT the|DET Nifty_50|CARDINAL index|NOUN was|VERB down|ADP 1.6%.Aurobindo|CARDINAL Pharma|PROPN ,|PUNCT the|DET largest|ADJ gainer|NOUN today|DATE ,|PUNCT up|ADV 6%_to|PERCENT Rs|VERB 638|CARDINAL after|ADP the|DET company|NOUN said|VERB it|PRON has|VERB received|VERB final_approval|NOUN from|ADP the|DET to|PART manufacture|VERB Sevelamer_Carbonate|ENT oral_suspension|NOUN ,|PUNCT 0.8|CARDINAL gm|PROPN and|CCONJ 2.4|CARDINAL gm|NOUN .|PUNCT
Sevelamer_Carbonate_oral_suspension|NOUN ,|PUNCT a|DET therapeutic_equivalent_generic_version|NOUN of|ADP Genzyme|ENT 's|PART Renvela|ENT oral_suspension|NOUN .|PUNCT
The|DET product|NOUN is|VERB being|VERB launched|VERB immediately|ADV .|PUNCT
Sevelamer_Carbonate_oral_suspension|NOUN is|VERB indicated|VERB for|ADP the|DET control|NOUN of|ADP serum_phosphorus|NOUN in|ADP patients|NOUN with|ADP chronic_kidney_disease|NOUN (|PUNCT CKD|ENT )|PUNCT on|ADP dialysis|NOUN .|PUNCT
The|DET approved_product|NOUN has|VERB an|DET estimated_market_size|NOUN of|ADP US$_140_million|MONEY for|ADP the_twelve_months_ending_April_2017|DATE according|VERB to|ADP IMS.was|VERB up|ADV 1.6%_to|PERCENT Rs|VERB 537|CARDINAL after|ADP receiving|VERB approval|NOUN from|ADP the|DET US_health_regulator|NOUN for|ADP anti-retroviral_drug."Zydus_Cadila|PROPN has|VERB received|VERB final_approval|NOUN from|ADP the|DET to|ADP market|NOUN Acyclovir_injection_USP_strengths|NOUN of|ADP 500_mg/vial_and_1,000_mg|QUANTITY /|SYM vial|NOUN ,|PUNCT "|PUNCT the|DET pharma_company|NOUN said|VERB in|ADP its|ADJ filing|NOUN .|PUNCT
Acyclov|ENT for|ADP Injection_USP|ENT which|ADJ caters|VERB to|ADP the|DET anti-viral_segment|NOUN will|VERB be|VERB produced|VERB at|ADP the|DET group|NOUN 's|PART formulations_manufacturing_facility|NOUN at|ADP Moraiya|ENT in|ADP Ahmedabad|ENT .|PUNCT
